Group
anti-CSF1R mAb
Group Profile
| Therapeutic Class | Monoclonal Antibodies (mAbs) |
| Drug Class | Other mAbs |
| Mechanism of Action | anti-CSF1R antibody |
| Drugs in group | Cabiralizumab |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Immunologically synergistic in principle (reprograms suppressive TAMs/MDSCs post-RT), not a DNA-level sensitizer (Shang et al. Frontiers Immununology 2024; Sanseviero et al. Nature Cancer 2026). No in-field DNA sensitization; class-specific effects (periorbital edema, hepatic/CK elevations) rather than radiation-side-effects potentiation are the main concern.
The data above refer to patients treated with anti-CSF1R mAb as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.